JAZZ : Analysis & Opinions

  1. Jazz Pharmaceuticals Public Limited Company (JAZZ): New Analyst ...

    January 5, 2015
    Jazz's third-quarter earnings of $2.07 per share were above the year-ago earnings of $1.61 per share. Quarterly revenues ...
  2. Jazz Pharmaceuticals Starts Defibrotide Rolling NDA Filing - ...

    December 15, 2014
    Jazz Pharmaceuticals (JAZZ) has started the rolling submission of a NDA for defibrotide.
  3. Wall Street's Latest Tax Craze... And How To Profit

    September 18, 2014
    A couple weeks ago in StreetAuthority Daily, we talked about some of Corporate America's latest financial engineering ...
  4. Capitalize On Wall Street's Latest Tax Craze

    September 18, 2014
    A couple weeks ago in StreetAuthority Daily, we talked about some of Corporate America's latest financial engineering ...
  5. Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry ...

    July 24, 2014
    Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
  6. The Celtic Tiger Roars Once Again

    March 21, 2014
    Everyone is Irish on St. Paddy’s Day. However, investors may want to keep that going with regards to their portfolios. After ...
  7. Four Breakout Stocks To Watch

    February 19, 2014
    These biotechnology and pharmaceutical stocks continue to put in new highs, but indicators are diverging.
  8. GW Pharma's Sativex Launched in Italy - Analyst Blog

    July 11, 2013
    GW Pharma announced that Sativex has been launched in Italy.
  9. Santarus Achieves New 52-Week High - Analyst Blog

    July 9, 2013
    Share price of Santarus reached a new 52-week high on Jul 8, 2013.
  10. Astellas/Vical Start TransVax Phase III Study - Analyst Blog

    June 27, 2013
    Astellas Pharma and its partner Vical commenced a multinational phase III registration study of TransVax to control cytomegalovirus ...
  11. Data from Bayer/JNJ's Xarelto Study - Analyst Blog

    June 25, 2013
    Bayer's announced that it will present data from a Xarelto clinical program.
  12. Ariad's Iclusig in GIST Phase II Study - Analyst Blog

    June 18, 2013
    The study will evaluate Iclusig's efficacy and safety in patients who have failed at least one tyrosine kinase inhibitor ...
  13. Perrigo in Expansion Mode - Analyst Blog

    June 18, 2013
    Perrigo has purchased Fera's eye-care portfolio.
  14. US Launch of Forest's Namenda XR - Analyst Blog

    June 17, 2013
    Namenda XR is a once-daily extended-release version of the company's immediate release formulation of Namenda.
  15. 10 Picks from 2 Strong Sectors

    June 10, 2013
    As we enter the bumpy summer months, large-cap US domestic stocks and health-care names are on Louis Navellier's list, and ...
  16. Jazz Initiates Erwinaze Trial - Analyst Blog

    December 5, 2012
    Jazz Pharmaceuticals (JAZZ) recently initiated a study on Erwinaze (asparaginase Erwinia chrysanthemi) for the treatment ...
  17. Some Stocks Starting To Shape Up

    September 7, 2011
    Some stocks are starting to look better despite the recent market weakness.
  18. Biotechs Ready To Roll

    February 16, 2011
    Biotechs Ready To Roll
  19. Biotech Stocks Looking Strong

    March 9, 2010
    Biotech Stocks Looking Strong
Trading Center